Takeda Pharmaceutical Co Ltd (4502)

26.4600 -0.0500 (-0.19%)
Closed EUR Disclaimer

Takeda Pharmaceutical Co Ltd Company Profile

Equity Type
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Contact Information
Tokyo,103-8668 Japan
81 3 3278 2111
81 3 3278 2000
Top Executives
Christophe Weber 56 2014 President, CEO & Representative Director
Andrew S. Plump 57 2015 President of Research & Development and Representative Director
Constantine Saroukos 51 2018 CFO & Representative Director
Masami Iijima 72 2021 Independent External Chair
Masato Iwasaki 64 2012 Representative Director
Shiro Kuniya 65 2013 Independent External Director
Koji Hatsukawa 71 2016 Head of Audit & Supervisory Committee
Steven S. Gillis 69 2019 Independent External Director
Jean-Luc Butel 66 2019 Independent External Director
Michel Orsinger 65 2016 Independent External Director
Yoshiaki Fujimori 71 2016 Member of Audit & Supervisory Committee
Olivier Bohuon 63 2019 Independent External Director
Emiko Higashi 64 2016 Member of Audit & Supervisory Committee Member
Ian T. Clark 62 2019 Independent External Director
Kimberly A. Reed 51 2022 Member of Audit & Supervisory Committee
John M. Maraganore 60 2022 Independent External Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.